Oxytocin vs Prostamax
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Oxytocin is a 9-amino acid neuropeptide produced in the hypothalamus with diverse roles in social bonding, trust, stress reduction, and sexual function. Exogenous administration is used therapeutically to improve social cognition, reduce anxiety, and enhance intimacy.
- Prostamax is a tetrapeptide bioregulator (Lys-Glu-Asp-Pro) developed by Professor Vladimir Khavinson, tissue-specific for the prostate gland. It supports prostate epithelial cell function, promotes normalization of prostate tissue, and is studied for its potential in benign prostatic hyperplasia (BPH), prostatitis, and prostate anti-aging. It is one of the more widely used Khavinson bioregulators among men over 40.
- Half-Life
- ~3–5 minutes (IV); ~30–60 minutes (intranasal, CNS effects persist longer)
- Short (minutes); sustained gene-regulatory effects
- Admin Route
- Intranasal, SubQ, IV
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 20–40 IU
- 10 mg per day
- Frequency
- As needed (not daily long-term)
- Daily for 10–30 days
- Key Benefits
- Enhances social bonding and trust
- Reduces social anxiety and fear of rejection
- Improves autism spectrum symptoms (social cognition)
- Reduces cortisol and stress reactivity
- Enhances sexual arousal and intimacy
- Promotes maternal behavior and bonding
- May improve depressive symptoms
- Appetite suppression and metabolic effects
- Supports normalization of prostate tissue architecture
- May reduce prostate enlargement associated with BPH
- Anti-inflammatory effects on prostatic tissue
- Reduces prostate cell apoptosis from oxidative stress
- Potential support in chronic prostatitis
- Anti-aging effects on prostate glandular tissue
- Complementary to conventional BPH therapies
- Side Effects
- Mild uterine cramping (avoid in pregnancy)
- Nasal irritation (intranasal)
- Headache
- Potential emotional over-attachment or jealousy amplification
- +2 more
- Generally well tolerated in available research
- Mild injection site reactions
- No significant adverse urological events reported at standard doses
- Stacks With
- —
- —